Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.

2 years ago

BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD, MBA…

CitiusTech Named a Leader and a Star Performer in Everest Group’s Payer Digital Services PEAK Matrix® Assessment 2023

2 years ago

PRINCETON, N.J.--(BUSINESS WIRE)--#AI--CitiusTech, a leading provider of healthcare technology services, solutions, and platforms, announced that it has been positioned as…

Red Light Holland Receives Building Permit for AEM Farms 80,000 Square Foot Mushroom Farm, Adding Substantial Future Production Capacity

2 years ago

New multi million dollar production facility will increase AEM Farm's mushroom production output by approximately 15-18 million dollars of domestic…

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

2 years ago

TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")…

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

2 years ago

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic…

Burr & Forman Provides Notice of Data Security Incident

2 years ago

BIRMINGHAM, Ala., Jan. 14, 2024 /PRNewswire/ -- Burr & Forman LLP ("Burr & Forman"), a law firm based in Birmingham,…

Tackling the Poor Sleep Pandemic: FRENZ Brainband by Earable Neuroscience Announces Global Sales After CES 2024 Innovation Award Win

2 years ago

FRENZ Brainband, a pioneering AI-powered sleep wearable initially introduced as a prototype at CES 2023, is now available for global…

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

2 years ago

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5…

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

2 years ago

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and…

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be

2 years ago

Cell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotechNEW YORK, Jan.…